Spark vet Furey steering Imvax into glioblastoma Phase II with $112M series C

A $112 million series C round will help Imvax move its autologous neoantigen immunotherapy into Phase II testing for glioblastoma. The therapy, which CEO John Furey told BioCentury is first in class, uses a patient’s own tumor cells to trigger a personalized immune system attack against a brain tumor.

Imvax Inc. was founded

Read the full 531 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers